Dominari (DOMH) Competitors $5.50 +0.28 (+5.36%) As of 07/16/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock DOMH vs. VNDA, VSTM, CDXS, AGEN, IRWD, SGMO, ACHV, FBIO, SABS, and CRISShould you be buying Dominari stock or one of its competitors? The main competitors of Dominari include Vanda Pharmaceuticals (VNDA), Verastem (VSTM), Codexis (CDXS), Agenus (AGEN), Ironwood Pharmaceuticals (IRWD), Sangamo Therapeutics (SGMO), Achieve Life Sciences (ACHV), Fortress Biotech (FBIO), SAB Biotherapeutics (SABS), and Curis (CRIS). These companies are all part of the "biotechnology" industry. Dominari vs. Its Competitors Vanda Pharmaceuticals Verastem Codexis Agenus Ironwood Pharmaceuticals Sangamo Therapeutics Achieve Life Sciences Fortress Biotech SAB Biotherapeutics Curis Vanda Pharmaceuticals (NASDAQ:VNDA) and Dominari (NASDAQ:DOMH) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, media sentiment, analyst recommendations, earnings and valuation. Which has stronger valuation & earnings, VNDA or DOMH? Dominari has lower revenue, but higher earnings than Vanda Pharmaceuticals. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than Dominari, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVanda Pharmaceuticals$198.77M1.43-$18.90M-$0.75-6.41Dominari$18.15M4.44-$14.70M-$4.50-1.22 Do analysts prefer VNDA or DOMH? Vanda Pharmaceuticals presently has a consensus price target of $16.50, indicating a potential upside of 243.04%. Given Vanda Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Vanda Pharmaceuticals is more favorable than Dominari.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vanda Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Dominari 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media prefer VNDA or DOMH? In the previous week, Dominari had 1 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 2 mentions for Dominari and 1 mentions for Vanda Pharmaceuticals. Dominari's average media sentiment score of 0.93 beat Vanda Pharmaceuticals' score of 0.63 indicating that Dominari is being referred to more favorably in the news media. Company Overall Sentiment Vanda Pharmaceuticals Positive Dominari Positive Do institutionals & insiders believe in VNDA or DOMH? 88.1% of Vanda Pharmaceuticals shares are owned by institutional investors. Comparatively, 42.5% of Dominari shares are owned by institutional investors. 10.0% of Vanda Pharmaceuticals shares are owned by insiders. Comparatively, 33.0% of Dominari shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is VNDA or DOMH more profitable? Vanda Pharmaceuticals has a net margin of -21.98% compared to Dominari's net margin of -167.73%. Vanda Pharmaceuticals' return on equity of -8.30% beat Dominari's return on equity.Company Net Margins Return on Equity Return on Assets Vanda Pharmaceuticals-21.98% -8.30% -6.85% Dominari -167.73%-91.67%-77.80% Which has more risk & volatility, VNDA or DOMH? Vanda Pharmaceuticals has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500. Comparatively, Dominari has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500. SummaryVanda Pharmaceuticals beats Dominari on 11 of the 17 factors compared between the two stocks. Get Dominari News Delivered to You Automatically Sign up to receive the latest news and ratings for DOMH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DOMH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DOMH vs. The Competition Export to ExcelMetricDominariMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$76.44M$2.41B$5.51B$9.31BDividend YieldN/A1.79%4.25%4.09%P/E Ratio-1.229.1828.1819.72Price / Sales4.44762.22439.19110.06Price / CashN/A160.6835.5357.53Price / Book0.964.698.235.67Net Income-$14.70M$30.99M$3.23B$257.51M7 Day Performance15.06%-0.20%-0.61%-0.16%1 Month Performance9.13%8.67%6.63%9.89%1 Year Performance195.70%-4.17%27.07%15.08% Dominari Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DOMHDominari0.7787 of 5 stars$5.50+5.4%N/A+195.7%$76.44M$18.15M-1.224News CoverageVNDAVanda Pharmaceuticals4.7021 of 5 stars$4.89flat$16.50+237.4%-22.8%$288.19M$201.35M-6.52290VSTMVerastem3.0952 of 5 stars$4.61-1.7%$13.38+190.1%+42.7%$254.47M$10M-1.4550CDXSCodexis3.4732 of 5 stars$2.66+3.1%$11.00+313.5%-22.9%$220.88M$59.35M-2.69250Positive NewsAGENAgenus4.2284 of 5 stars$4.92-5.0%$14.00+184.6%-64.1%$135.71M$99.52M-0.57440IRWDIronwood Pharmaceuticals4.3616 of 5 stars$0.76+6.3%$4.78+531.0%-89.2%$123.63M$351.41M-3.82220Positive NewsSGMOSangamo Therapeutics2.7094 of 5 stars$0.51-0.7%$4.50+785.8%+4.7%$118.68M$57.80M-1.31480Positive NewsACHVAchieve Life Sciences3.1172 of 5 stars$2.15+3.6%$14.33+568.2%-44.5%$74.79MN/A-1.6120FBIOFortress Biotech2.5341 of 5 stars$1.97+3.1%$21.00+966.0%-3.0%$58.40M$57.67M-0.89170Positive NewsSABSSAB Biotherapeutics3.7279 of 5 stars$2.04+4.1%$13.25+549.5%-9.7%$18.95M$1.32M-0.55140CRISCuris2.5785 of 5 stars$1.80+3.7%$17.00+842.4%-73.8%$18.83M$11.20M-0.2960Positive News Related Companies and Tools Related Companies Vanda Pharmaceuticals Competitors Verastem Competitors Codexis Competitors Agenus Competitors Ironwood Pharmaceuticals Competitors Sangamo Therapeutics Competitors Achieve Life Sciences Competitors Fortress Biotech Competitors SAB Biotherapeutics Competitors Curis Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DOMH) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dominari Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dominari With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DOMH Stock Alerts